Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, adult: General and other
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 162 for your search:
Start Over
Light Sedation or Intubated General Anesthesia in Reducing Complications and Length of Hospital Stay in Patients With Brain Cancer Undergoing Craniotomy
Status: Active
Phase: Phase IV
Type: Supportive care, Treatment
Age: 19 and over
Trial IDs: OSU-12161, NCI-2014-01110, 2014C0007, NCT02193568
Temozolomide with or without Veliparib in Treating Patients with Newly Diagnosed Glioblastoma Multiforme
Status: Temporarily closed
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A071102, NCI-2014-00616, CALGB-A071102, NCT02152982
P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: Tg 511-15-01, NCI-2015-01577, NCT02414165
Radiation Therapy or Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Anaplastic Glioma or Low Grade Glioma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: N0577, NCI-2011-01915, CDR0000640442, EORTC-26081-22086, EudraCT-2008-007295-14, NCCTG-N0577, NCT00887146
Combination Chemotherapy in Treating Patients with Non-Metastatic Extracranial Ewing Sarcoma
Status: Temporarily closed
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and under
Trial IDs: AEWS1031, NCI-2011-02611, CDR0000687639, COG-AEWS1031, NCT01231906
Carboplatin with or without Vincristine Sulfate in Treating Younger Patients with Previously Untreated Low Grade Glioma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and younger
Trial IDs: LCH 14C03, NCI-2015-01146, 2014-15932, LGG-14C03, NCT02455245
A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: VB-111-215, NCI-2015-01344, NCT02511405
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ICT-107-301, NCI-2015-01811, NCT02546102
Study of Nivolumab Compared to Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-498, NCI-2016-00144, 2015-003739-37, NCT02617589
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: OT-15-001, NCI-2016-01159, NCT02796261
Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: IRB00002868, NCI-2013-00786, 2868, CR00002456, OHSU-8507, OHSU-2868, OHSU-SOL-04058-L, NCT00303849
Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients with Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 1 to 30
Trial IDs: IRB00005056, NCI-2013-00790, 5056, MR00042551, OHSU-5056, NCT00983398
Trastuzumab in Treating Leptomeningeal Metastases in Patients with HER2-Positive Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 10C03, NCI-2011-00110, STU00040150, STU00040150-MOD0003, NCT01325207
Everolimus and Sorafenib Tosylate in Treating Patients with Recurrent High-Grade Gliomas
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16-C-0011, NCI-2015-02100, BTTC09-01, P152430, NCT01434602
Bevacizumab, Minocycline Hydrochloride, and Radiation Therapy in Treating Patients with Recurrent Glioma
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: HCI55264, NCI-2012-01118, 55264, NCT01580969
Liposomal Rhenium Re 186 in Treating Patients with Recurrent Glioma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CTRC# 12-02, NCI-2014-00900, 1149367, 1-874640-1, 193831, 20141749, HSC20140450X, NCI-2014-00412, NCT01906385
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: TPI-287-17, NCI-2014-01453, NCT01933815
Plerixafor after Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed High Grade Glioma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: BRN0023, NCI-2013-02012, 5136, NCT01977677
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 16 and over
Trial IDs: NLG2102, NCI-2014-02063, NCT02052648
MK-3475 in Combination with MRI-guided Laser Ablation in Recurrent Malignant Gliomas
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201501072, NCI-2015-00119, 14-x326, NCT02311582
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCB 24360-204 / ECHO-204, NCI-2015-00040, NCT02327078
Study of Marizomib With Bevacizumab in Subjects With WHO Grade IV Malignant Glioma Followed by a Trial of Single-Agent Marizomib
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MRZ-108, NCI-2015-00711, NCT02330562
Multitargeted Tyrosine Kinase Inhibitor PLX3397 in Treating Younger Patients with Refractory Leukemias or Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 30
Trial IDs: 15-C-0093, NCI-2015-00457, 150093, P141640, NCT02390752
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioblastoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15702, NCI-2015-02229, H9H-MC-JBEF, NCT02423343
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-ST-209, NCI-2016-00105, NCT02586857
Start Over